Adverse Event Reporting: Sponsors, FDA Disagree On Responsibilities To IRBs
Executive Summary
Drug developers are pushing back against FDA's effort to place on them the major responsibility for providing the information that the institutional review boards need for continuing reviews
You may also be interested in...
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
Single IRB Policy For Multi-Site Trials May Soon Get White House OK; NCI Hopeful
The White House appears close to finalizing a policy that would allow multi-site clinical trials to use only one institutional review board, which National Cancer Institute and other officials think could speed up and improve the process.
CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms
Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry